Inside Health Policy, Inside Drug Pricing | FDA: Inspection Lag Puts Generic Drug Exclusivity at Risk

Cathy Burgess comments on how the U.S. Food and Drug Administration is likely to use remote evaluations to resolve as many issues as possible before returning to onsite inspections of facilities.

This week, CMS announced a data request for information (RFI) in an effort to increase Medicare Advantage (MA) transparency and the Senate Finance Committee released a plan to prevent and mitigate generic drug shortages.

Cathy Burgess is quoted on how the Food and Drug Administration might conduct remote inspections of drug manufacturing facilities amid COVID-19.

This past week saw a flurry of legislative action in Washington as both chambers of Congress took up bills dealing with drug pricing and surprise billing. Read more about these proposals and other news below.

Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in healthcare regulations, notices, and guidance; federal legislation and congressional committee action; reports, studies, and analyses; and other health policy news.